PLoS ONE (Jan 2016)

Trisubstituted-Imidazoles Induce Apoptosis in Human Breast Cancer Cells by Targeting the Oncogenic PI3K/Akt/mTOR Signaling Pathway.

  • Chakrabhavi Dhananjaya Mohan,
  • V Srinivasa,
  • Shobith Rangappa,
  • Lewis Mervin,
  • Surender Mohan,
  • Shardul Paricharak,
  • Sefer Baday,
  • Feng Li,
  • Muthu K Shanmugam,
  • Arunachalam Chinnathambi,
  • M E Zayed,
  • Sulaiman Ali Alharbi,
  • Andreas Bender,
  • Gautam Sethi,
  • Basappa,
  • Kanchugarakoppal S Rangappa

DOI
https://doi.org/10.1371/journal.pone.0153155
Journal volume & issue
Vol. 11, no. 4
p. e0153155

Abstract

Read online

Overactivation of PI3K/Akt/mTOR is linked with carcinogenesis and serves a potential molecular therapeutic target in treatment of various cancers. Herein, we report the synthesis of trisubstituted-imidazoles and identified 2-chloro-3-(4, 5-diphenyl-1H-imidazol-2-yl) pyridine (CIP) as lead cytotoxic agent. Naïve Base classifier model of in silico target prediction revealed that CIP targets RAC-beta serine/threonine-protein kinase which comprises the Akt. Furthermore, CIP downregulated the phosphorylation of Akt, PDK and mTOR proteins and decreased expression of cyclin D1, Bcl-2, survivin, VEGF, procaspase-3 and increased cleavage of PARP. In addition, CIP significantly downregulated the CXCL12 induced motility of breast cancer cells and molecular docking calculations revealed that all compounds bind to Akt2 kinase with high docking scores compared to the library of previously reported Akt2 inhibitors. In summary, we report the synthesis and biological evaluation of imidazoles that induce apoptosis in breast cancer cells by negatively regulating PI3K/Akt/mTOR signaling pathway.